Deconstructing ecstasy: The politics of MDMA research

Addiction Research and Theory

Volumn 8, Issue 6, 2000, Pages 549-588

  Grob, Charles S ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0345982700     PISSN: 16066359     EISSN: None     Source Type: Journal    
DOI: 10.3109/16066350008998989     Document Type: Article

References (138)

1. Adamson, S. (1985). Through the Gateway of the Heart: Accounts of Experiences with MDMA and Other Empathogenic Substances. San Francisco: Four Trees Publications.
2. Adamson, S. and Metzner, R. (1988). The nature of the MDMA experience and its role in healing, psychotherapy and spiritual practice. ReVision, 10, 59-72.
3. Ali, S. F., Newport, G. D., Scallet, A. C., Binienda, Z., Ferguson, S. A. and Bailey, J. R. (1993). Oral administration of MDMA produces selective 5-HT depletion in the non-human primate. Neurotoxicol. Teratol., 15, 91-96.
4. ++ dependent toxicity linked to release. Brain Res., 510, 97-103.
5. Azmitia, E. C. and Whitaker-Azmitia, P. M. (1991). Awakening the sleeping giant: anatomy and plasticity of the brain serotonergic system. J. Clin. Psychiatry, 52 (suppl), 4-16.
6. Bakalar, J. and Grinspoon, J. B. (1990). Testing psychotherapies and drug therapies: the case of psychedelic drugs. In S. J. Peroutka, (Ed.). Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA. Holland: Kluwer, pp. 37-52.
7. Battaglia, G., Yeh, S. Y. and DeSouza, E. B. (1988). MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol. Biochem. Behav., 29, 269-274.
8. Beck, J. (1993). Ecstasy and the rave scene: historical and cross-cultural perspectives. CEWG Dec: 424-431.
9. Beck, J. and Morgan, P. A. (1986). Designer drug confusion: a focus on MDMA. J. Drug. Education, 16, 287-302.
10. Beck, J. and Rosenbaum, M. (1994). Pursuit of Ecstasy: The MDMA Experience. State University of New York Press: Albany, New York.
11. Bolla, K. I., McCann, U. D. and Ricaurte, G. A. (1998). Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology, 51, 1532-1537.
12. Brody, S., Krause, Veit, R. and Rau, H. (1998). Cardiovascular autonomic dysregulation users of MDMA ("ecstasy"). Psychopharmacol., 136, 390-393.
13. Broening, H. W., Bowyer, J. F. and Slikker, W. (1995). Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (±)3,4-methylenedioxymethampethamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response. J. Pharmacol. Exp. Ther., 275, 325-333.
14. Buchanan, J. F. and Brown, C. R. (1988). Designer drugs: a problem in clinical toxicology. Med. Toxicol., 3, 1-17.
15. Buck, A., Gucker, P., Vollenweider, F. X. and Burger, C. (2000). Evaluation of serotonergic transporter using PET and 11C-(+)-McN-5652: assessment of methods. J. Cerebral Blood Flow Metabolism, in press.
16. Burchett, S. A. and Bannon, M. J. (1997). Serotonin, dopamine and norepinephrine transporter mRNAs: heterogeneity of distribution and response to 'binge' cocaine administration. Molecular Brain Res., 49, 95-102.
17. Burger, A. J., Sherman, H. B., Charlamb, M. J., Kim, J., Asinas, L. A., Flickner, S. R. and Blackburn, G. L. (1999). Low prevalence of valvular heart disease in 226 phenterminefenfluramine protocol subjects prospectively followed for up to 30 months. J. Am. Coll. Cardiol., 34, 1153-1158.
18. Caccia, S., Ballabio, M., Guiso, G., Rochetti, M. and Garattini, S. (1982). Species differences in the kinetics of metabolism of fenfluramine isomers. Arch. Int. Pharmacodyn., 258, 15-28.
19. Caccia, S., Anelli, M., Ferrarese, A., Fracasso, C. and Garattini, S. (1993). The role of d-norfenluramine in the indole-depleting effect of d-fenfluramine in the rat. Eur. J. Pharmacol., 223, 71-77.
20. Capdevila, M. (1995). MDMA o el Extasis Quimico. Barcelona: Los Libros De La Liebre De Marzo.
21. Ceccherelli, F., Costa, C., Ischia, S., Ischia, A., Giron, G. and Alletri, G. (1989). Cerebral tryptophan metabolism in humans in relation to malignant pain. Funct. Neurol., 4, 341-353.
22. Chappell, S. and Mordenti, J. (1991). Extrapolation of toxicological and pharmacological data from animals to humans. In B. Tests, (Ed.). Advances in Drug Research. San Diego: Academic Press, pp. 1-116.
23. Colado, M. I., Murray, T. K. and Green, A. R. (1993). 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. Br. J. Pharmacol., 108, 583-589.
24. Colado, M. I., Williams, J. L. and Green, A. R. (1995). The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4-methylenedioxyampethamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br. J. Pharmacol., 115, 1281-1289.
25. Collin, M. (1998). Altered State: The Story of Ecstasy Culture and Acid House. London: Serpent's Tail.
26. Costa, C., Ceccherelli, F., Bettero, A., Marin, G., Mancusi, L. and Allegri, G. (1984). Tryptophan, serotonin and 5-hydroxyindoleacetic acid levels in human CSF in relation to pain. In H. G. Schlossberger, W. Kochen, B. Linzen and H. Steinhart (Eds). Progress in Tryptophan and Serotonin Research, pp. 413-416.
27. Cuomo, J. J., Dyment, P. G. and Gammino, V. M. (1994). Increasing use of "ecstasy" (MDMA) and other hallucinogens of a college campus. J. Amer. College Health Assoc., 42, 271-274.
28. Curran, H. V. (1998). Is ecstasy (MDMA) a human neurotoxin? Novartis Foundation Conference. London, December 4.
29. Curran, H. V. and Travill, R. A. (1997). Mood and cognitive effects of ±3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): weekend 'high' followed by mid-week low. Addiction, 92, 821-831.
30. Dalgarno, P. J. and Shewan, D. (1996). Illicit use of ketamine in Scotland. J. Psychoactive Drugs, 28, 191-199.
31. DeRios, M. D. and Grob, C. S. (1994). Hallucinogens, suggestibility and adolescence in cross-cultural perspective. Yearbook Ethnomedicine, 3, 113-132.
32. Derome-Tremblay, M. and Nathan, C. (1989). Fenfluramine studies. Science, 243, 991.
33. Doblin, R. (1996). MAPS MDMA analysis project. MAPS, 6, 11-13.
34. Dowling, G. P., McDonough, E. T. and Bost, R. O. (1987). "Eve" and "ecstasy": a report of five deaths associated with the use of MDEA and MDMA. JAMA, 257, 1615-1617.
35. Downing, J. (1986). The psychological physiological effects of MDMA on normal volunteers. J. Psychoactive Drugs, 18, 335-339.
36. Eisner, B. (1989). Ecstasy: The MDMA Story. Berkeley: Ronin Publishing.
37. Eliade, M. (1951). Shamanism: Archaic Techniques of Ecstasy. Paris: Librarie Payot.
38. Ellison, G. (1995). The N-methyl-D-aspartate antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of dementias. Brain Res. Rev., 20, 250-267.
39. Erowid, E. (1998a). Comments on MDMA neurotoxicity study: a prospective guinea pig. http://www.erowid.org?chemicals/mdma/mdma_journal3/mdma_journal3_comment3. shtml.
40. Erowid, E. (1998b). MDMA neurtoxicity study: questioning the correlation between increased MDMA use and decreased binding - an analysis of figure 4 of the McCann-Ricaurte MDMA study results. http://www.erowid.org/chemicals/mdma/ mdma_journal3_statistics.shtml.
41. Furnari, C., Ottaviano, V., Rosati, F. and Tondi, V. (1998). Identification of 3,4-methylenedioxymethamphetamine analogs encountered in clandestine tablets. Forensic Science International, 92, 49-58.
42. Gasser, P. (1995a). Die psycholytische psychotherapie in der Schweiz (1988-1993). Jahrbuch fur Transkulturelle Medizin und Psychotherapie, 6, 143-162.
43. Gasser, P. (1995b). The psycholytic therapy in Switzerland from 1988-1993: a follow-up study. MAPS, 5, 3-7.
44. Gijsman, G., Vrekes, R., van Gervan, J. and Cohen, A. (1999). MDMA study. Neuropsychopharmacol., 21, 597.
45. Greer, G. and Tolbert, R. (1986). Subjective reports of the effects of MDMA in a clinical setting. J. Psychoactive Drugs, 18, 319-327.
46. Grinspoon, L. and Bakalar, J. B. (1979). Psychedelic Drugs Reconsidered. New York: Basic Books.
47. Grinspoon, L. and Bakalar, J. B. (1986). Can drugs be used to enhance the psychotherapeutic process? Am. J. Psychotherapy, 40, 393-404.
48. Grob, C. S. (1998). Psychiatric research with hallucinogens: what have we learned? Heffter. Rev. Psychedelic Research, 1, 8-20.
49. Grob, C. S. and DeRios, M. D. (1992). Adolescent drug use in cross-cultural perspective. J. Drug Issues, 22, 121-138.
50. Grob, C. S. and Poland, R. E. (1997). MDMA. In J. H. Lowinson, P. Ruiz, R. B. Millman and J. G. Langrod (Eds). Substance Abuse: A Comprehensive Textbook, Third Edition. Baltimore: Williams and Wilkins, pp. 269-275.
51. Grob, C. S., Bravo, G. L. and Walsh, R. N. (1990). Second thoughts on 3,4-methylenedioxymethamphetamine (MDMA) neurotoxicity. Arch. Gen. Psychiatry, 47, 288.
52. Grob, C. S., Bravo, G. L., Walsh, R. N. and Liester, M. B. (1992). The MDMA-neurotoxicity controversy: implications for clinical research with novel psychoactive drugs. J. Nerv. Ment. Dis., 180, 355-356.
53. Grob, C. S., Poland, R. E., Chang, L. and Ernst, T. (1996). Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary findings. Behav. Brain Research, 73, 103-107.
54. Harrington, R. D., Woodward, J. A., Hooton, T. M. and Horn, J. R. (1999). Life-threatening interactions between HTV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch. Intern. Med., 159, 2221-2224.
55. Harris Research Center (1992). Young peoples poll.
56. Harris, D., Baggott, Jones, R. T. and Mendelson, J. (1999). MDMA pharmacokinetics and physiological and subjective effects in humans. CPDD, 59.
57. Harvey, J. A., McMaster, S. E. and Yunger, L. M. (1975). p-Chloroamphetamine: selective neurotoxic action in brain. Science, 187, 841-843.
58. Hatzidimitriou, G., McCann, U. D. and Ricaurte, G. A. (1999). Altered serotonin innervation patterns in the forebrain of monkeys treated with MDMA seven years previously: factors influencing abnormal recovery. J. Neurosci., 191, 5096-5107.
59. Heinz, A., Higley, J. D., Gorey, J. G., Saunders, R. C., Jones, D. W., Hommer, D., Zajicek, K., Suomi, S. J., Lesch, K. P., Weinberger, D. R. and Linnoila, M. (1998). In vivo association between alcohol intoxication, aggression, and serotonin transporter availability in nonhuman primates. Am. J. Psychiatry, 155, 1023-1028.
60. Henry, J. A., Jeffreys, K. J. and Dawling, S. (1992). Toxicity and deaths from 3,4-methlyenedioxymethamphetamine ("ecstasy"). Lancet, 340, 384-387.
61. Hekmatpanah, C. R. and Peroutka, S. J. (1990). 5-hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methylenedioxymethamphetamine and related agents. Eur. J. Pharmacol., 177, 95-98.
62. Hewitt, K. E. and Green, A. R. (1994). Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ("Ecstasy"). Neuropharmacol., 33, 1589-1595.
63. Inciyan, E. (2000). Ecstasy's high-risk agenda. The Guardian, February 24.
64. Jansen, K. L. R. (1998). Ecstasy (MDMA) dependence. Drug Alcohol Dependence, 53, 121-124.
65. Johnson, M. P. and Nichols, D. E. (1990). Comparative serotonin neurotoxicity of the steroisomers of fenfluramine and norfenfluramine. Pharmacol. Biochem. Behav., 36, 105-109.
66. Karel, R. (1993). Fluoxetine may protect against MDMA neurotoxicity. Psychiatric News, August 6.
67. Krystal, J. H., Price, L. H., Opsahl, C., Ricaurte, G. A. and Heninger, G. R. (1992). Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function? Am. J. Drug Alcohol Abuse, 18, 331-341.
68. King, L. A. (1998). Comments. Novartis Foundation Conference: Is Ecstasy (MDMA) A Human Neurotoxin? London, December 4.
69. Kuikka, J. T. and Ahonen, A. K. (1999). Letter on toxic effect of MDMA on brain serotonin neurons. Lancet, 353, 1269.
70. Kuroda, Y., Watanabe, Y. and McEwen, B. S. (1994). Tianeptine decreases both serotonin transporter mRNA and binding sites in rat brain. Eur. J. Pharmacol., 268, R3-R5.
71. Lawn, J. C. (1986). Schedules of controlled substances: scheduling of 3,4-methylenedioxymethampehtamine (MDMA) into schedule I. Federal Register, 51, 36552-36560.
72. Lesch, K. P., Aulakh, C. S., Wolozin, B. L., Tolliver, T. J., Hill, J. L. and Murphy, D. L. (1993). Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants. Molecular Brain Res., 17, 31-35.
73. Lieberman, J. and Aghajanian, G. (1999). Caveat emptor: researcher beware. Neuropsychopharmacol., 21, 472.
74. Malberg, J. E. and Seiden, L. S. (1998). Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetmaine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat J. Neurosci., 18, 5086-5094.
75. Manchanda, S. and Connolly, M. J., (1993). Cerebral infarction in association with ecstasy abuse. Postgrad Med. J., 69, 874-879.
76. Marchant, M. C., Breen, M. A., Wallace, D., Bass, S., Taylor, A. R., Ings, R. M. J. and Campbell, B. (1992). Comparative biodisposition and metabolism of 14C-(+/-)-fenfluramine in mouse, rat, dog and man. Xenobiotica, 12, 1251-1266.
77. Mas, M., Farre, M., De La Torre, R., Roset, P. N., Ortuno, J., Segura, J. and Cami, J. (1999). Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J. Pharmacol Exp. Ther., 290, 136-145.
78. Matthews, A. and Jones, C. (1992). Spate of British ecstasy deaths puzzles experts. Int. J. Drug Policy, 3, 4.
79. McCann, U. D. and Ricaurte, G. A. (1995). On the neurotoxicity of MDMA and related amphetamine derivatives. J. Clin. Psychopharmacol., 15, 295-296.
80. McCann, U. D. and Ricaurte, G. A. (2000). Caveat emptor: editors beware. Neuropsychopharmacol, in press.
81. McCann, U., Hatzidimitriou, G., Ridenour, A., Fischer, C., Yuan, J., Katz, J. and Ricaurte, G. (1994). Dexfenfluramine and serotonin neurotoxicity: further preclinical evidence that clinical caution is indicated. J. Pharmacol. Exp. Ther., 269, 792-798.
82. McCann, U. D., Mertl, M., Eligulashvili, V. and Ricaurte, G. A., (1999). Cognitive performance in (±)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users: a controlled study. Psychpharmacol., 143, 417-425.
83. McCann, U. D., Szabo, Z., Scheffel, U., Dannals, R. F. and Ricaurte, G. A., (1998). Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet, 352, 1433-1437.
84. McEntee, W. J. and Crook, T. H. (1991). Serotonin, memory and the aging brain. Psychopharmacol., 103, 143-149.
85. McKenna, D. J. and Peroutka, S. J. (1990). Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine. J. Neurochem., 54, 14-22.
86. Molliver, M. E., Berger, U. V., Mamounas, L. A., Molliver, D. C., O'Hearn, E. and Wilson, M. A. (1990). Neurotoxicity of MDMA and related compounds: anatomic studies. Ann. NY. Acad. Sci., 600, 640-664.
87. Nelson, K. T. (1999). MDMA and memory impairment: proven or not? MAPS, 9(3), 6-8.
88. Newmeyer, J. A. (1993). X at the crossroads. J. Psychoactive Drugs, 25, 341-342.
89. NIDA Capsules (1993). CAP 16, U.S. Department of Health and Human Services, National Institute on Drug Abuse.
90. NIDA [1999] www.monitoringthefuture.org
91. O'Callaghan, J. P. (1993). Quantitative features of reactive gliosis following toxicant-induced damage to the CNS. Ann. NY Acad. Sci., 679, 195-210.
92. O'Callaghan, J. P. (1995). Commentary on article by Ricaurte and colleagues. MAPS, 6(1), 13.
93. O'Callaghan, J. P. and Miller, D. B. (1993). Quantification of reactive gliosis as an approach to neurotoxicity assessment. In L. Erinoff (Ed.). Assessing Neurotoxicity of Drugs of Abuse. National Institute on Drug Abuse Monograph 136, Washington, D.C: U.S. Government Printing Office, 188-212.
94. O'Callaghan, J. P. and Miller, D. B. (1994). Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther., 270, 741-751.
95. Parrott, A. (1998). Is ecstasy (MDMA) a human neurotoxin? Novartis Foundation Conference. London, December 4.
96. Peroutka, S. J. (1987). Incidence of recreational use of 3,4-methlenedioxymethamphetamine (MDMA, "ecstasy") on an undergradulate campus. New England J. Med., 317, 1542-1543.
97. Peroutka, S. J. (1988). Relative insensitivity of mice to 3,4-methylenedioxymethamphetaamine neurotoxicity. Res. Commun. Subs. Abuse, 9, 193-206.
98. Pletscher, A., Burkar, W. P., Bruderer, H. and Gey, K. F. (1963). Decrease of cerebral 5-hydroxytryptamine and 5-hydroxyindolacetic acid by arylalkylamine. Life Sci., 11, 828-833.
99. Price, L. H., Ricaurte, G. A., Krystal, J. H. and Henninger, G. R. Neuroendocrine and mood responses to intravenous 1-tryptophan in 3,4-methylenedioxymethamphet-amine (MDMA) users. Arch. Gen. Psychiatry, 46, 20-22.
100. Randall, T. (1992). Ecstasy-fuled "rave" parties become dances of death for English youths. JAMA, 268, 1505-1506.
101. Rezvani, A. H., Garges, P. L., Miller, D. B. and Gordon, C. J. (1992). Attenuation of alcohol consumption by MDMA (Ecstasy) in two strains of alcohol-preferring rats. Pharmacol. Biochem. Behav., 43, 103-110.
102. Ricaurte, G., Bryan, G., Strauss, L., Seiden, L. and Schuster, C. (1985). Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science, 229, 986-988.
103. Ricaurte, G. A., Finnegan, K. T., Irwin, I. and Langston, J. W. (1990). Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: preliminary observations. Ann. NY Acad. Sci., 600, 699-708.
104. Riedlinger, T. J. and Riedlinger, J. E. (1994). Psychedelic and entactogenic drugs in the treatment of depression. J. Psychoactive Drugs, 26, 41-55.
105. Robinson, T. E., Castandea, E. and Whishaw, I. Q. (1993). Effects of cortical serotonin depletion induced by 3,4-methylenedioxymethamphetamine (MDMA) on behavior, before and after additional cholinergic blockade. Neuropsychopharmacol., 8, 77-85.
106. Romano, A. G. and Harvey, J. A. (1993). MDMA enhances associative and nonassociative learning in the rabbit. Pharmacol. Biochem. Behav., 47, 289-293.
107. Sanders-Bush, E., Bushing, J. A. and Sulser, F. (1975). Long-term effects of p-chloroamphetamine and related drugs of central serotonergic mechanisms. J. Pharmacol. Exp. Ther., 192, 33-40.
108. Saunders, N. (1993). E is for Ecstasy. London: Saunders.
109. Saunders, N. (1995). Ecstasy and the dance culture. London: Saunders.
110. Saunders, N. and Doblin, R. (1996). Ecstasy: Dance Trance and Transformation. Oakland, California: Quick American Archives.
111. Schifano, F., DiFuria, L., Forz, G., Minicuci, N. and Bricolo, R. (1998). MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients. Drug Alcohol Dependence, 52, 85-90.
112. Schiller, N. B. (1999). Fen/phen and valvular heart disease: if it sounds too bad to be true, perhaps it isn't. J. Am. Coll. Cardiol., 34, 1159-1162.
113. Schmidt, C. J. (1987). Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther., 240, 1-7.
114. Schmidt, C. J. and Taylor, V. L. (1987). Depression of rat brain tryptophan hydroxylase following the acute administration of methylenedioxymethamphetamine. Biochem. Pharmacol., 36, 4095-4102.
115. Schmidt, C. J., Abbate, G. M., Black, C. K. and Taylor, V. L. (1990). Selective 5-HT2 receptor antagonists protect against the neurotoxicity of methylenedioxymethamphetamine in rats. J. Pharmacol. Exp. Ther., 255, 478-483.
116. Schultes, R. E. and Hofmann, A. (1992). Plants of the Gods: Their Sacred, Healing and Hallucinogenic Powers. Rochester, Vermont: Healing Arts Press.
117. Sferios, E. (1999). Report from DanceSafe: laboratory analysis program reveals DXM tablets sold as "ecstasy". MAPS Bull, 9(4), 47.
118. Sharkey, A. (1996). Sorted or distorted. The Guardian, 26 January: 2-4.
119. Shewan, D., Dalgarno, P. and King, L. A. (1996). Tablets often contain substances in addition to, or instead of, ecstasy. Lancet, 313, 423-424.
120. Shulgin, A. T., (1986). The background and chemistry of MDMA. J. Psychoactive Drugs, 18, 291-304.
121. Shulgin, A. T. (1990). History of MDMA. In S. J. Peroutka (Ed.). Ecstasy: The Clinical, Pharmacological and Neurotoxicological Effects of the Drug MDMA. Holland: Kluwer, 1-20.
122. Shulgin, A. T. and Nichols, D. E. (1978). Characterization of three new psychotomimetics. In R. Stillman and R. Willete (Eds). The Psychopharmacology of Hallucinogens. New York: Pergamon Press, pp. 74-83.
123. Shulgin, A. and Shulgin, A. (1991). PIHKAL. Berkeley: Transform Press.
124. Slikker, W., Ali, S. F., Scallet, A. C., Frith, C. H., Newport, G. D. and Bailey, J. R. (1988). Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). Toxicol. Appl. Pharmacol., 94, 448-457.
125. Slikker, W. J., Holson, R. R., Ali, S. F., Kolta, M. G., Paule, M. G., Scallet, A. C., McMillan, D. E., Bailey, J. R., Hong, J. S. and Scalzo, R. M. (1989). Behavioral and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate. Neurotoxicol., 10, 529-542.
126. Sprague, J. E. and Nichols, D. E. (1995). The monoamine oxidase-B inhibitor 1-deprenyl protects against 3,4-methylenedioxymethampehtmaine-induced lipid peroxidation and long-term serotonergic deficits. J. Pharmacol. Exp. Ther., 273, 667-673.
127. Sprague, J. E., Everman, S. L. and Nichols, D. E. (1998). An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. NeuroToxicol., 19, 427-442.
128. Suomi, S. J. (1999). Attachment in rhesus monkeys. In J. Cassidy and P. R. Shaver (Eds). Handbook of Attachment: Theory, Research and Clinical Applications. New York: Guilford Press, pp. 181-197.
129. Sylvester, R. (1995). Ecstasy: the truth. The Sunday Telegraph, 19 Nov: 24.
130. Tancer, M. and Schuster, C. R. (1997). Serotonin and dopamine system interactions in the reinforcing properties of psychostimulants: a research strategy. MAPS, 7(3), 5-11.
131. Tancer, M. and Johanson, C. E. (1999). Subjective responses to MDMA and mCPP: A human dose run-up study. CPDD, 160.
132. Vollenweider, F., Gamma, A., Liechti, M. and Huber, T. (1998). Psychological and cardiovascular effects and short-term sequelae of MDMA (ecstasy) in MDMA-naive healthy volunteers. Neuropsychopharmacol., 19, 241-251.
133. Vollenweider, F. X., Gamma, A., Liechti, M. and Huber, T. (1999). Is a single dose of MDMA harmless? Neuropsychopharmacol., 21, 598-600.
134. Watanabe, Y., Sakai, R. R., McEwen, B. S. and Mendelson, S. (1993). Stress and antidepressant effects on hippocampal and cortical 5-HT1A and 5-HT2 receptors and transport sites for serotonin. Brain Res., 615, 87-94.
135. Winstock, A. R. and King, L. A. (1996). Tablets often contain substances in addition to, or instead of, ecstasy, such as ketamine. Lancet, 313, 423-424.
136. Wolff, K., Hay, A. W. M., Sherlock, K. and Conner, M. (1996). Contents of "ecstasy". Lancet, 346, 1100-1101.
137. Young, F. (1986). Opinion and recommended ruling, findings of fact, conclusions of law and decision of administrative law judge: submitted in the matter of MDMA scheduling. U.S. Drug Enforcement Administration Docket no. 84-88.
138. Ziporyn, T. (1986). A growing industry and menace: makeshift laboratory's designer drugs. JAMA, 256, 3061-3063.